A new Phase III clinical trial called the Myeloma XII trial, also known as the ACCoRd trial, has recruited its first patients.
The purpose of the Myeloma XII trial is to see if using a novel drug called ixazomib (Ninlaro®) can strengthen the effect of a second high-dose therapy and stem cell transplant (HDT-SCT).
You can find out more about the trial, including how to find out if you are suitable to take part, below.
What is the Myeloma XII trial?
Myeloma XII is one of the latest in a series of national myeloma trials developed by the National Cancer Research Institute, which have been responsible for some notable discoveries in myeloma.
The Myeloma XII trial has been developed based on results from another national myeloma trial called the Myeloma X trial. The Myeloma X trial showed that a second high-dose therapy and autologous stem cell transplant (HDT-SCT) slows down the progression of myeloma in comparison to treatment with standard chemotherapy. However, Myeloma X also showed that the depth and duration of response to the second HDT-SCT was inferior to those reported for the first HDT-SCT.
The purpose of the Myeloma XII trial is to see if using a novel drug called ixazomib (Ninlaro®) can strengthen the effect of a second HDT-SCT. The trial will study the effects of ixazomib when used both as induction treatment and as a consolidation and maintenance treatment following a second HDT-SCT.
All patients taking part will receive ixazomib as part of their induction treatment, but then will be randomised to different treatment pathways – see our Infosheet on the Myeloma XII trial for more details.
Neither patients nor their doctor can choose how patients will be randomised.
Who is eligible to take part in the trial?
The Myeloma XII trial is for myeloma patients at their first relapse and requiring treatment, and who have already had one previous HDT-SCT which gave them at least 12 months of remission or stable disease.
There are other criteria that patients must meet in order to participate in the trial, known as eligibility criteria. Speak to your doctor to find out more about the trial eligibility criteria.
Where is the trial open?
It is currently open at 58 hospitals across the UK within 44 NHS trusts, with many more expected to take part in the coming weeks and months. For an up-to-date list of hospitals taking part in the trial, see our Myeloma Trial Finder.
What should I do if I want to take part in the trial?
Talk to your doctor in the first instance – they are best placed to advise you on whether the trial is running at your hospital, or one nearby, and whether or not you are eligible to take part.
You can read more about the Myeloma XII trial in our Infosheet
If you would like to talk to someone about what the trial entails, please call the Myeloma Infoline on 0800 980 3332 or email AskTheNurse@myeloma.org.uk